More on ACAD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.63 |
|
|||
| Open | $25.37 | ||||
| 52 Wk High | $42.49 | ||||
| 52 Wk Low | $16.64 | ||||
| Day High | $25.84 | ||||
| Day Low | $25.20 | ||||
| P/E | N/A | ||||
| EPS | $-0.42 | ||||
| Volume | 1,207,376 | ||||
- Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
- Acadia Pharmaceuticals (ACAD) PT Raised to $36 at RBC Capital
- Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
- H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
- Form 4 ACADIA PHARMACEUTICALS For: Jun 26 Filed by: Kihara James
- Acadia Pharmaceuticals (ACAD) PT Raised to $37 at Deutsche Bank
- Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Canaccord
- Mizuho Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)
- Acadia Pharma (ACAD) call put ratio 6.8 calls to 1 put with a focus on July 25 calls
- Acadia Pharmaceuticals (ACAD) PT Raised to $35 at Citi, Opens 90-Day Upside CW
Entities mentioned with ACAD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Needham & Company | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
